Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biocurpain Force is a natural, multi-herb traditional medicine and dietary supplement developed and manufactured by SOHO Global Health (specifically through its subsidiary SOHO Industri Pharmasi) in Indonesia. It is formulated as a film-coated tablet containing a combination of 350 mg of Curcuma longa rhizoma extract (standardized as BCM-95) and 150 mg of Boswellia serrata extract (standardized as Bospure). Biocurpain Force is indicated for the relief of joint pain and inflammation associated with chronic osteoarthritis and arthritis. The supplement operates via a dual-action anti-inflammatory mechanism: curcumin from Curcuma longa inhibits cyclooxygenase-2 (COX-2) and downregulates inflammatory cytokines, while boswellic acids from Boswellia serrata inhibit arachidonate 5-lipoxygenase (5-LOX). This dual COX/LOX inhibition provides synergistic pain relief and cartilage protection with a favorable gastrointestinal safety profile compared to conventional non-steroidal anti-inflammatory drugs (NSAIDs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biocurpain Force.